about
Profiling immunity to HIV vaccines with systems biologyGlycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugsSocial justice and HIV vaccine research in the age of pre-exposure prophylaxis and treatment as preventionWhen to start antiretroviral therapy: the need for an evidence base during early HIV infectionBroad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry.Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoitesA mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine developmentAn open-ended plea for the development of a global database of HIV vaccine responses.Frequent and strong antibody-mediated natural killer cell activation in response to HIV-1 Env in individuals with chronic HIV-1 infection.Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media.Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.CD4 binding determinant mimicry for HIV vaccine design.Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds.The evolutionary significance of certain amino acid substitutions and their consequences for HIV-1 immunogenicity toward HLA's A*0201 and B*27.
P2860
Q27010629-769E6078-75F2-480D-885B-24A25CA0E542Q33829799-154AACFA-FBA5-4925-B0DB-0E2BD0FF7624Q33854562-73867970-DBEF-44F3-98C5-F56D9B1B7E0DQ34773308-D1E4CE0E-3984-4114-A3BA-FC34D45733BEQ34908895-5E42A263-E26D-440B-A6F7-8B3EF9457A5BQ35111844-057A3DDC-6F01-463E-9C43-7A95FE3AA3A9Q35298899-B4CB09CE-04A7-4D8D-8E1E-15536ED426E7Q35659519-9902918E-AD95-4A03-93B9-A517CEE3EAF9Q36086748-5E596FC8-88BF-4074-A30C-139A2B5F7062Q36412202-ACDD67AB-3CCF-438E-A706-3BAC1C9D253BQ36442232-80E09F63-D25F-4D86-A4FB-5F76939D4E2FQ36469664-47D08A13-5C1B-49C4-9A09-49C93B8C7761Q38820461-71462191-24EF-43C5-8E00-A329BFB145BEQ39259705-3CF7D431-EA8A-4342-98F8-136936F7D517
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HIV vaccines: progress to date.
@en
HIV vaccines: progress to date.
@nl
type
label
HIV vaccines: progress to date.
@en
HIV vaccines: progress to date.
@nl
prefLabel
HIV vaccines: progress to date.
@en
HIV vaccines: progress to date.
@nl
P1433
P1476
HIV vaccines: progress to date
@en
P2093
Anthony D Kelleher
Christopher R Andersen
P304
P356
10.2165/11585400-000000000-00000
P577
2011-03-01T00:00:00Z